Xet 20 Dosage/Direction for Use

Paroxetine should be administered once daily with food, preferably in the morning. The tablet(s) should be swallowed rather than chewed.
Depression: The recommended dose is 20 mg/day. Some patients not responding to a 20 mg dose may benefit from dose increases, in 10 mg/day increments, up to a maximum of 50 mg/day. The dosage should be reviewed and adjusted within 2 to 3 weeks of initiation of therapy and thereafter as deemed clinically appropriate. Any changes in dosage should occur at intervals of at least one week.
Obsessive Compulsive Disorder (OCD): The recommended dose is 40 mg/day. Patients should start on an initial dose of 20 mg/day and the dose can then be increased in weekly 10 mg/day increments. Doses up to a maximum of 60 mg/day may benefit some patients.
Panic Disorder: The recommended dose is 40 mg/day. Patients should begin treatment at a dose of 10 mg/day with the dose being adjusted in weekly 10 mg/day increments according to their individual response. Doses up to a maximum of 60 mg/day may benefit some patients.
Social Anxiety Disorder/Social Phobia: The recommended dose is 20 mg/day. Some patients not responding to a 20 mg dose may benefit from having dose increases in 10 mg increments as required, up to a maximum of 50 mg/day according to the patients response. It is generally recommended that a course of antidepressant drug treatment should continue for a sufficient period to ensure the patient is free from symptoms. This period may be several months for depression but can be longer for OCD and Panic Disorder.
Generalised Anxiety Disorder: The recommended dose is 20 mg daily. Some patients not responding to a 20 mg dose may benefit from having dose increases in 10 mg increments as required, up to a maximum of 50 mg/day according to the patient's response.
Posttraumatic Stress Disorder: For the majority of patients, the recommended starting and maintenance dose is 20 mg daily. However, some patients not responding to a 20 mg dose may benefit from having dose increases in 10 mg increments as required, up to a maximum of 50 mg/day according to the patient's response.
The use of Paroxetine beyond 12 weeks has not been investigated in clinical trials.
Use in Elderly: Increased plasma concentrations of Paroxetine occur in elderly subject. But the range of concentration overlaps those observed in younger subjects. Dosing should begin with the adult starting dose and may be increased by weekly 10 mg/day increments up to 40 mg/day, according to the patient's response.
Use in Children and Adolescent Patients (under 18 years of age): Paroxetine should not be used in patients under 18 years of age.
Renal/Hepatic Impairment: Increased plasma concentrations of Paroxetine occur in patients with renal impairment (creatinine clearance <30 mL/min) or severe hepatic impairment. Dosages should be restricted to the lower end of the dosage range.
Discontinuation of Paroxetine: As with other psychoactive medications, abrupt discontinuation should generally be avoided. The taper phase regimen used in recent clinical trials involved a decrease in the daily dose by 10 mg/day at weekly intervals. When a daily dose of 20 mg/day was reached, patients were continued on this dose for one week before treatment was stopped. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.